WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561366
CAS#: 1431724-30-9
Description: PACA, also known as N-Propargyl Caffe amide, potentiates NGF-induced neurite outgrowth and attenuates 6-hydroxydopamine neurotoxicity in neuronal culture. Insufficient production of nerve growth factor (NGF) is implicated in Parkinson's disease (PD).
Hodoodo Cat#: H561366
Name: PACA
CAS#: 1431724-30-9
Chemical Formula: C12H11NO3
Exact Mass: 217.07
Molecular Weight: 217.224
Elemental Analysis: C, 66.35; H, 5.10; N, 6.45; O, 22.10
Synonym: PACA; N-Propargyl Caffeamide; N-propargyl Caffeate Amide;
IUPAC/Chemical Name: 3-(3,4-Dihydroxyphenyl)-N-2-propyn-1-yl-2-propenamide
InChi Key: HLHSUNWAPXINQU-GQCTYLIASA-N
InChi Code: InChI=1S/C12H11NO3/c1-2-7-13-12(16)6-4-9-3-5-10(14)11(15)8-9/h1,3-6,8,14-15H,7H2,(H,13,16)/b6-4+
SMILES Code: O=C(NCC#C)/C=C/C1=CC=C(O)C(O)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 217.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Luo D, Zhao J, Cheng Y, Lee SM, Rong J. N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP(+)-Induced Neurons via Promoting the Conversion of proNGF to NGF. Mol Neurobiol. 2017 Mar 21. doi: 10.1007/s12035-017-0486-6. [Epub ahead of print] PubMed PMID: 28321769.
2: Yang C, Zhao J, Cheng Y, Le XC, Rong J. N-Propargyl Caffeate Amide (PACA) Potentiates Nerve Growth Factor (NGF)-Induced Neurite Outgrowth and Attenuates 6-Hydroxydopamine (6-OHDA)-Induced Toxicity by Activating the Nrf2/HO-1 Pathway. ACS Chem Neurosci. 2015 Sep 16;6(9):1560-9. doi: 10.1021/acschemneuro.5b00115. Epub 2015 Jul 16. PubMed PMID: 26147318.